Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications
Conditions
Interventions
Intervention1: Empagliflozin: 25mg tablet orally given once daily for a duration of 3 months
Control Intervention1: Standard treatment for type 2 diabetes mellitus.: standard treatment prescribed for
Sponsors
SRM Insitute of Science and Technology
Eligibility
Inclusion criteria
Inclusion criteria: Estimated glomerular filtration rate 45 to 90 ml per minute . Diabetic patients HbA1C greater than 6.5 percent Patients with haemoglobin less than 13.0 g per dL in males. Haemoglobin less than 12.0 g per dL in females.
Exclusion criteria
Exclusion criteria: End Stage Renal Disease patients Stage 4 Patients with hereditary iron metabolism disorders. Patients with Type 1 Diabetes mellitus. Patients with pre-existing Urinary tract or Genital infections and patients who develop this complication during the study. Patient with pyelonephritis. Patients already taking diuretics. Pregnant and Lactating women. Treatment with any other investigational drug within the previous 30 days of inclusion in the study. Any therapy or condition that would pose a risk to the patient or make it difficult to comply with study requirements. Difficulty in Socio Culture Communication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum erythropoietin, ferritin and transferrin saturation will be assessed at baseline and after 3months.Timepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| nilTimepoint: nil | — |
Countries
India
Contacts
Public ContactArunshankar P
SRM Institute of Science and Technology
Outcome results
None listed